SCHEDULE: T. Rowe Price Boosts IMMUNOME Stake to 12.2%

T. Rowe Price Investment Management, Inc. has disclosed a 12.2% beneficial ownership stake in IMMUNOME INC, holding over 10.6 million shares.

Summary

• T. Rowe Price Investment Management, Inc. reported beneficial ownership of 10,644,674 shares of IMMUNOME INC common stock.
• This ownership represents 12.2% of the class of securities.
• T. Rowe Price Investment Management, Inc. holds sole voting power over 10,638,638 shares.
• T. Rowe Price Investment Management, Inc. holds sole dispositive power over 10,644,674 shares.
• The shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of IMMUNOME INC.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional ownership stake by a reputable firm like T. Rowe Price is generally viewed positively, signaling confidence in the issuer.

Positives

• A significant institutional investor, T. Rowe Price Investment Management, Inc., has taken a substantial 12.2% stake in IMMUNOME INC, indicating confidence in the company.
• The investment was made in the ordinary course of business, suggesting a long-term investment perspective rather than an activist one.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding IMMUNOME INC's future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from T. Rowe Price Investment Management, Inc.)
• "T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." (Statement from T. Rowe Price Investment Management, Inc.)

Industry Context

The disclosure of a significant stake by a major investment manager like T. Rowe Price in a company like IMMUNOME INC is a common occurrence in the biotechnology sector, reflecting institutional interest in companies with potential for growth and innovation.

Stakeholder Impact

• Shareholders: Increased institutional ownership can be perceived as a positive signal, potentially enhancing investor confidence and liquidity.
• Company Management: A large institutional holder may bring increased scrutiny and engagement, though T. Rowe Price has stated no intent to influence control.

Key Dates

Keywords

IMMUNOME INC, T. Rowe Price, Investment Management, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology